Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 49, Issue 2-3, 2000, Pages 93-99

  Wan Mohamad, W B ^a   Tun Fizi, A ^a   Ismail, R B ^a   Mafauzy, M ^a  

^a SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Glibendamide; Multiple daily doses; Single daily dose

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SAFETY;

EID: 0033843782     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(00)00138-8     Document Type: Article

References (12)

1. O'Sullivan D.J. Blood glucose variation and clinical experience with glibenclamide in diabetes mellitus. Br. Med. J. 2:1970;572-574.
2. Urquhurt J. Ascertaining how much compliance is enough with out patient antibiotic regimes. Postgrad. Med. J. 68(Suppl. 3):1992;49-50.
3. Matsuda A-, Kuwya T., Sugita Y., Kawashima K. Plasma level's of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res. 15:1983;425-428.
4. Jaber L.A., Slaughter R.L., Antak E.J., Welshman I.R. Comparison of paharmacokinetics and pharmacodynamics of short and long-term glyburide therapy in NIDDM. Diabetes Care. 17:1994;1300-1306.
5. Hermann L.S., Schersten B., BiuM P.O., KjelIsrom T., Lindgarde F., Melander A Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations, A double-blind controlled study. Diabetes Care. 17:1994;1100-1109.
6. Rains S.G.H., Wilson G.A., Richmond W., Elkeles R.S. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med. 5:1988;653-658.
7. Hermann L.S., Schersten B., Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabetic Med. 11:1994;953-960.
8. Baynes C., Elkeles R.S., Henderson D., Richmond W., Johnston D.G. The effects of glibenclamide on glucose homeostasis and lipoprotein metabolism in poorly controlled type 2 diabetes mellitus. Horm Metab Res. 25:1993;96-101.
9. Haffner SM, Hanefeld K, Fischer S., Fuscker K-, Leonhardt W. Glibenclamide, but not acarbose increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care. 20:1997;1430-1434.
10. Chan J.C.N., Cocfram C.S., Tomlinson B., Walden R.J., Critchley J. Metabolic and haemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 16:1993;1035-1038.
11. Ferner R.E., Neil H.A.W. Sulphonylureas and hypoglycemia. Br Med J. 296:1988;949-950.
12. Jennings AM, Wilson R-NI, Ward J.D. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 12:1989;203-208.